This article was published on April 21, 2022
Modafinil has an FDA indication “to improve wakefulness in adult patients excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD)”.
Armodafinil has an FDA indication “to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD)”.
A dopamine and norepinephrine reuptake inhibitor (DNRI) with an FDA indication “to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA)”.
A histamine-3 (H3) receptor antagonist/inverse agonist with an FDA indication “for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy“.
Medications for excessive daytime sleepiness (due to sleep apnea, narcolepsy, or shift work disorder)
Copyright © 2022, Simple and Practical Medical Education, LLC. All rights reserved. May not be reproduced in any form without express written permission.
Disclaimer: The content on this website is provided as general education for medical professionals. It is not intended or recommended for patients or other laypersons or as a substitute for medical advice, diagnosis, or treatment. Patients must always consult a qualified health care professional regarding their diagnosis and treatment. Healthcare professionals should always check this website for the most recently updated information.